Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Stanford University · RWTH Aachen University · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
276
total citations
- FWCI
- 48.92
- Percentile
- 100%
- References
- 26
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Medicine
- Proteinuria
- Clinical endpoint
- Renal function
- Internal medicine
- Placebo
- Nephropathy
- Kidney disease
No related works found for this paper.